Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Recruiting Observational Study
Cerebral Hemorrhage Acute Lobar Haematoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
128 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital; * Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up. Exclusio…
Contacts

Teodora PARVU

04.66.68.32.61

teodora.parvu@chu-nimes.fr

CONTACT